A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours.

BACKGROUND: EMD 521873 (Selectikine), an immunocytokine comprising a DNA-targeting antibody, aimed at tumour necrosis, fused with a genetically modified interleukin-2 (IL-2) moiety, was investigated in this first-in-human phase I study. METHODS: Patients had metastatic or locally advanced solid tumours failing previous standard therapy. Selectikine was administered as a 1-hour intravenous infusion on 3 consecutive days, every 3weeks. A subgroup of patients also received 300mg/m(2) cyclophosphamide on day 1 of each cycle. Escalating doses of Selectikine were investigated with the primary objective of determining the maximum tolerated dose (MTD). RESULTS: Thirty-nine patients were treated with Selectikine alone at dose levels from 0.075 to 0.9mg/kg, and nine were treated at doses of 0.45 and 0.6mg/kg in combination with cyclophosphamide. A dose-dependent linear increase of peak serum concentrations and area under curve was found. The dose-limiting toxicity was grade 3 skin rash at the 0.9mg/kg dose-level; the MTD was 0.6mg/kg. Rash and flu-like symptoms were the most frequent side-effects. No severe cardiovascular side-effects (hypotension or vascular leak) were observed. At all dose-levels, transient increases in total lymphocyte, eosinophil and monocyte counts were recorded. No objective tumour responses, but long periods of disease stabilisation were observed. Transient and non-neutralising Selectikine antibodies were detected in 69% of patients. CONCLUSIONS: The MTD of Selectikine with or without cyclophosphamide administered under this schedule was 0.6mg/kg. The recommended phase II dose was 0.45-0.6mg/kg. Selectikine had a favourable safety profile and induced biological effects typical for IL-2.

Estimates of radiation-absorbed dose to kidneys in patients treated with 90Y-ibritumomab tiuxetan.

The aim of the present study was to retrospectively estimate the absorbed dose to kidneys in 17 patients treated in clinical practice with 90Y-ibritumomab tiuxetan for non-Hodgkin's lymphoma, using appropriate dosimetric approaches available. METHODS: The single-view effective point source method, including background subtraction, is used for planar quantification of renal activity. Since the high uptake in the liver affects the activity estimate in the right kidney, the dose to the left kidney serves as a surrogate for the dose to both kidneys. Calculation of absorbed dose is based on the Medical Internal Radiation Dose methodology with adjustment for patient kidney mass. RESULTS: The median dose to kidneys, based on the left kidney only, is 2.1 mGy/MBq (range, 0.92-4.4), whereas a value of 2.5 mGy/MBq (range, 1.5-4.7) is obtained, considering the activity in both kidneys. CONCLUSIONS: Irrespective of the method, doses to kidneys obtained in the present study were about 10 times higher than the median dose of 0.22 mGy/MBq (range, 0.00-0.95) were originally reported from the study leading to Food and Drug Administration approval. Our results are in good agreement with kidney-dose estimates recently reported from high-dose myeloablative therapy with 90Y-ibritumomab tiuxetan.

Estudi teòric pràctic de la solubilitat de noves mescles aquoses de nitrats alcalins per climatització per absorció accionada tèrmicament a alta temperatura

Investigación realizada a partir de una estancia como profesor visitante en el Departamento de Ingeniería Mecánica de la Universitat Rovira i Virgili. Las soluciones acuosas de LiNO3 tienen una gran potencialidad para ser utilizadas como fluidos de trabajo en ciclos de absorción a altas temperaturas. La adición de otros nitratos y/o nitritos alcalinos mejora, entre otras propiedades, su solubilidad en H2O, el principal inconveniente de estas soluciones. La información bibliográfica sobre la solubilidad de estas es prácticamente inexistente, por eso, en este trabajo se ha realizado un estudio teórico-práctico de la solubilidad de algunos de estos sistemas.(...)

Estudio de cerámicas nanoestructuradas mediante difracción de rayos X y microscopía electrónica de alta resolución

Este proyecto trata sobre la determinación de las relaciones epitaxiales que se dan entre una capa de NGO (Oxido de Neodimio-Galio) y una capa depositada de CGO (Óxido de Cerio dopado con Gadolinio). Con ello buscamos estudiar indirectamente como podemos producir las dislocaciones antes citadas mediante la tensión superficial que se crea al dar lugar un crecimiento heteroepitaxial auto-ensamblado de nanohilos sobre un substrato. Para utilizar en el futuro esta cerámica nanoestructurada como plantillas de superconductores. Abordaremos este objetivo mediante dos vertientes distintas. Por un lado, mediante el estudio de una muestra mediante difracción de rayos X en dos dimensiones (DRX2). Y paralelamente mediante su visualización usando Microscopía Electrónica de Transmisión (MET).

A control flow prototype for a dose recommending device for chronic myeloid leukemia patients

In this paper we present a prototype of a control flow for an a posteriori drug dose adaptation for Chronic Myelogenous Leukemia (CML) patients. The control flow is modeled using Timed Automata extended with Tasks (TAT) model. The feedback loop of the control flow includes the decision-making process for drug dose adaptation. This is based on the outputs of the body response model represented by the Support Vector Machine (SVM) algorithm for drug concentration prediction. The decision is further checked for conformity with the dose level rules of a medical guideline. We also have developed an automatic code synthesizer for the icycom platform as an extension of the TIMES tool.

Desarrollo de nuevas Funcionalidades para la Aplicación WebMap del GIS Corporativo de una empresa de distribución de agua en alta

La present memòria és el resultat del Projecte final del Màster en Tecnologia de la Informació Geogràfica, realitzat en la Universitat Autònoma de Barcelona, curs 2007-2009. Aquest document és per a il•lustrar el treball realitzat en a l'empresa Auding en conjunt en col•laboració amb la Universitat Autònoma de Barcelona. L'objectiu del projecte va ser és la creació de noves funcionalitats per a un GIS corporatiu d'una empresa de distribució d'aigua en alta. Aquest GIS és estratègic, doncs ja que permet millorar el tractament de la informació, la difusió de les dades, la planificació i la presa de decisions corporatiu.

Successful treatment of trilateral retinoblastoma with conventional and high-dose chemotherapy plus radiotherapy: a case report.

Trilateral retinoblastoma (TRB) is a rare condition characterized by an intracranial neuroblastic tumor associated with bilateral or unilateral retinoblastoma (RB). The outcome is almost always fatal. An 18-month-old patient with familial bilateral RB was referred for a pineal lesion detected on a screening by magnetic resonance imaging. The child, considered inoperable by 2 different neurosurgical teams, was treated with conventional chemotherapy (methotrexate, vincristine, vepeside, cyclophosphamide, and carboplatin) plus tandem transplantation (vepeside/carboplatin and thiotepa/mephalan) followed by local radiotherapy. At 80 months from the diagnosis of TRB, the patient is alive and in complete remission, with no neuropsychologic consequences. An early and aggressive treatment may improve the prognosis of TRB.